CARY, N.C.--(BUSINESS WIRE)--The Melanoma Research Foundation Breakthrough Consortium (MRFBC) has launched a new clinical trial to assess the impact of concomitant administration of bevacizumab (Avastin) with vemurafenib (Zelboraf) in patients with BRAFV600 mutation positive metastatic melanoma.
MRFBC has selected Biologics to be its sole distribution partner in overseeing the trial’s drug supply, patient-specific distribution, and accountability reporting. Biologics will also provide a customized quality assurance program to ensure randomization is upheld and to reduce waste.
Help employers find you! Check out all the jobs and post your resume.
